These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 26108695)

  • 1. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
    Jagannathan S; Abdel-Malek MA; Malek E; Vad N; Latif T; Anderson KC; Driscoll JJ
    Leukemia; 2015 Nov; 29(11):2184-91. PubMed ID: 26108695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
    Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
    Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
    Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
    Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
    Jaganathan S; Malek E; Vallabhapurapu S; Vallabhapurapu S; Driscoll JJ
    Oncotarget; 2014 Dec; 5(23):12358-70. PubMed ID: 25481044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
    Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
    Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma.
    Ninkovic S; Harrison SJ; Quach H
    Expert Rev Hematol; 2020 Nov; 13(11):1201-1210. PubMed ID: 32990063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
    Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
    J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
    Milani M; Rzymski T; Mellor HR; Pike L; Bottini A; Generali D; Harris AL
    Cancer Res; 2009 May; 69(10):4415-23. PubMed ID: 19417138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
    Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
    Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.
    Adomako A; Calvo V; Biran N; Osman K; Chari A; Paton JC; Paton AW; Moore K; Schewe DM; Aguirre-Ghiso JA
    BMC Cancer; 2015 May; 15():444. PubMed ID: 26025442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
    Rasche L; Menoret E; Dubljevic V; Menu E; Vanderkerken K; Lapa C; Steinbrunn T; Chatterjee M; Knop S; Düll J; Greenwood DL; Hensel F; Rosenwald A; Einsele H; Brändlein S
    Clin Cancer Res; 2016 Sep; 22(17):4341-9. PubMed ID: 27029491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
    Zhao Y; Zhang K; Li G; Zhang X; Shi D
    PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
    Dalva-Aydemir S; Bajpai R; Martinez M; Adekola KU; Kandela I; Wei C; Singhal S; Koblinski JE; Raje NS; Rosen ST; Shanmugam M
    Clin Cancer Res; 2015 Mar; 21(5):1161-71. PubMed ID: 25542900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo anti-melanoma action of metformin.
    Janjetovic K; Harhaji-Trajkovic L; Misirkic-Marjanovic M; Vucicevic L; Stevanovic D; Zogovic N; Sumarac-Dumanovic M; Micic D; Trajkovic V
    Eur J Pharmacol; 2011 Oct; 668(3):373-82. PubMed ID: 21806981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
    Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
    Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
    Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
    Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.